Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376370 | 1.00 | POLB (0.51) | POLBMEN1KMT2ADPP4KDM4E | |
| SCHEMBL2376236 | 0.90 | TACR1 (0.45) | POLBDPP4KDM4ESMN1; SMN2METAP1 | |
| SCHEMBL2373519 | 0.89 | KDM2B (0.47) | POLBDPP4KDM4ESMN1; SMN2METAP1 | |
| SCHEMBL2373508 | 0.89 | KDM2B (0.47) | POLBDPP4KDM4ESMN1; SMN2METAP1 | |
| SCHEMBL2376445 | 0.89 | DPP4 (0.46) | DPP4KDM4ESMN1; SMN2METAP1DPP7 | |
| SCHEMBL2376451 | 0.89 | DPP4 (0.46) | DPP4KDM4ESMN1; SMN2METAP1DPP7 | |
| SCHEMBL2374734 | 0.87 | DPP4 (0.46) | DPP4KDM4ESMN1; SMN2METAP1DPP7 | |
| SCHEMBL2374722 | 0.87 | DPP4 (0.46) | DPP4KDM4ESMN1; SMN2METAP1DPP7 | |
| SCHEMBL2376389 | 0.87 | POLB (0.65) | POLBMEN1KMT2AFAAH | |
| SCHEMBL2376394 | 0.87 | POLB (0.65) | POLBMEN1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | POLB 1882/4885MEN1 2324/4885KMT2A 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.